查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001301

核子医学市场报告：趋势、预测与竞争分析（至2035年）

Nuclear Medicine Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球核子医学市场前景广阔，肿瘤学、甲状腺疾病和心臟病学领域预计将迎来成长机会。预计2026年至2035年，全球核医市场将以7.4%的复合年增长率成长，到2035年市场规模预计将达到150亿美元。推动该市场成长要素包括标靶治疗的日益普及、早期诊断方法的广泛应用以及对个人化医疗日益增长的需求。

  • 根据 Lucintel 的预测，治疗性核子医学在预测期内有望呈现较高的成长率，并按类型划分。
  • 从应用领域来看，肿瘤学领域预计将呈现最高的成长率。
  • 从区域来看，亚太地区预计在预测期内将呈现最高的成长率。

核子医学市场的新趋势

在技​​术进步、个人化医疗需求日益增长以及对各种疾病早期诊断和治疗的日益重视的推动下，核医学市场正在快速发展。随着医疗服务提供者寻求更有效、创伤更小的治疗方案，市场在影像技术、放射性药物和治疗通讯协定都取得了显着创新。这些进步不仅提高了诊断的准确性，也扩大了核子医学在各个医学领域的应用范围。以下关键趋势突显了正在塑造这一充满活力的行业的变革性变化及其对相关人员的影响。

  • 影像技术的进步：PET/CT 和 PET/MRI 等混合影像系统的融合正在革新诊断能力。这些先进工具能够提供高解析度影像，更精确地定位病灶，并改善病患预后。随着技术的日益精进和普及，医疗机构能够更早、更准确地诊断疾病，从而实现更有效的治疗并降低医疗成本。
  • 个人化放射性药物的应用日益广泛：个人化放射性药物的研发使得个人化治疗方案成为可能。这些特化化合物可针对特定的疾病标记物，从而提高疗效并最大限度地减少副作用。这一趋势对癌症治疗的影响尤其显着，因为精准医疗正在改变患者管理模式并提高生存率，进而推动客製化核医解决方案市场的成长。
  • Theragunostik需求不断增长：Theragunostik结合了影像学和标靶治疗，使用同一种放射性药物。这种方法可以即时监测治疗反应，并根据需要调整治疗方案。 Theragunostik的日益普及正在推动市场成长，尤其是在肿瘤学领域，因为它提供了更有效、更个人化的治疗选择，并促进了放射性药物研发的创新。
  • 监管和报销体系变革：不断变化的法规结构和报销政策正在影响市场动态。核子医学影像核准流程的简化和保险覆盖范围的扩大正在加速医疗机构对该技术的采用。这些变革正在加速新产品的市场准入，促进更广泛的临床应用，并最终使患者更容易获得先进的诊断和治疗方案。
  • 拓展新兴市场：医疗基础设施的改善以及人们对核医学益处的日益认可，正在推动新兴经济体的市场扩张。对人力资源发展、基础设施和法规结构的投资，也促进了这些地区对核子医学技术的应用。这一趋势正在扩大全球市场覆盖范围，实现收入来源多元化，并推动创新以满足多样化的医疗保健需求。

总之，这些趋势正透过技术进步、个人化医疗的实现、临床应用的拓展以及地域覆盖范围的扩大，重塑整个核子医学市场。因此，该产业正展现出强劲的成长势头，有望实现持续成长、改善患者预后，并进一步将核医融入主流医疗实践。

核子医学市场近期趋势

核子医学市场正经历快速成长，这主要得益于技术创新、临床应用拓展以及对个人化医疗日益增长的需求。这些趋势正在改变诊断和治疗流程，扩大市场覆盖范围，并改善患者预后。相关人员正大力投资研发和基础建设，以掌握新兴机会。随着产业的不断发展，了解这些关键成长领域对于在这个充满活力的领域进行策略规划和投资决策至关重要。

  • 技术进步：先进的影像技术和放射性药物正在提高诊断准确性和治疗效果。诸如混合影像系统（PET/CT、SPECT/CT）等创新技术能够实现病灶的精准定位，并减少侵入性操作。这些进步正在拓展临床应用，吸引投资，并提高全球普及率。安全性的提升和手术时间的缩短也提高了病患的接受度，最终推动市场成长，并促进产品研发创新。
  • 临床应用拓展：核子医学的应用范围正在不断扩大，在标靶癌症治疗、循环系统、神经病学和感染疾病管理等领域均有新的适应症。这一多元化发展得益于多项研究表明，与传统治疗方法相比，核医学能够改善治疗效果并减少副作用。随着临床证据的积累，医疗专业人员对核医学影像技术的接受度日益提高，从而带动了对放射性药物和设备需求的成长。这一趋势正在显着扩大市场规模，并加速新产品的研发。
  • 投资与基础设施扩建：各国政府和私人企业正大力投资核医基础设施，包括生产设施、研究中心和临床基地。这些投资旨在增强区域能力，尤其是在新兴市场，并确保供应链的稳定性。基础设施的扩建将有助于增加核医学检测数量，并促进医疗专业人员的培训。这些发展对于市场成长、扩大核医服务的覆盖范围以及推动该领域的创新至关重要。
  • 监管支持和报销政策：有利的法规结构和报销政策正在推动核医学检测的普及。各国政府正在简化新型放射性药物的核准流程，并为诊断和治疗用途提供保险覆盖。这些支持减轻了医疗服务提供者和患者的经济负担，并加速了市场渗透。更清晰的指南和报销方案也促进了创新，并确保了该行业的永续发展。
  • 新兴经济体市场扩张：经济的快速成长和健康意识的提高正在推动核医学在新兴市场的应用。对医疗基础设施的投资、慢性病盛行率的上升以及政府的各项倡议，都在扩大核医服务的覆盖范围。本地化生产和伙伴关係正在降低成本并改善供应链。这种扩张正在开闢新的收入来源，实现市场多元化，并将新兴经济体打造成为核子医学的关键成长中心。

这些趋势正透过技术进步、临床应用拓展以及基础设施和医疗资源的改善，重塑整个核子医学市场。新兴经济体的投资增加、扶持政策推出以及市场扩张，正在推动成长和创新。因此，核子医学产业正走在持续扩张的道路上，不断改善诊断和治疗方案，最终造福全球患者。这些发展正在塑造一个更充满活力、更便利、更创新的核医格局。

目录

第一章执行摘要

第二章 市场概览

  • 背景与分类
  • 供应链

第三章 市场趋势与预测分析

  • 宏观经济趋势与预测
  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章：全球核子医学市场：按类型划分

  • 吸引力分析：按类型
  • 诊断核子医学
  • 治疗性核子医学

第五章 全球核子医学市场：依应用领域划分

  • 吸引力分析：依目的
  • 肿瘤学
  • 甲状腺
  • 循环系统
  • 其他的

第六章 区域分析

第七章：北美核子医学市场

  • 北美核子医学市场：按类型划分
  • 北美核子医学市场：依应用领域划分
  • 美国核子医学市场
  • 加拿大核医学市场
  • 墨西哥核子医学市场

第八章：欧洲核子医学市场

  • 欧洲核子医学市场：按类型划分
  • 欧洲核子医学市场：依应用领域划分
  • 德国核子医学市场
  • 法国核子医学市场
  • 义大利核子医学市场
  • 西班牙核子医学市场
  • 英国核子医学市场

第九章：亚太地区核子医学市场

  • 亚太地区核子医学市场：按类型划分
  • 亚太地区核子医学市场：依应用领域划分
  • 中国核子医学市场
  • 印度核子医学市场
  • 日本核子医学市场
  • 韩国核子医学市场
  • 印尼核子医学市场

第十章：世界其他地区的核子医学市场

  • 其他地区的核子医学市场：按类型
  • 其他地区的核子医学市场：按应用领域划分
  • 中东核子医学市场
  • 南非核子医学市场
  • 非洲核子医学市场

第十一章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析
  • 市占率分析

第十二章 机会与策略分析

  • 价值链分析
  • 成长机会分析
  • 新趋势：全球核子医学市场
  • 战略分析

第十三章：价值链中主要企业的公司概况

  • 竞争分析概述
  • Cardinal Health
  • GE Healthcare
  • Jubilant Pharma
  • Novartis
  • Curium Pharma
  • SIEMENS
  • Lantheus
  • Bracco Imaging
  • Bayer
  • Eli Lilly

第十四章附录

The future of the global nuclear medicine market looks promising with opportunities in the oncology, thyroid, and cardiology markets. The global nuclear medicine market is expected to reach an estimated $15 billion by 2035 with a CAGR of 7.4% from 2026 to 2035. The major drivers for this market are the increasing use of targeted therapies, the rising adoption of early diagnosis methods, and the growing demand for personalized treatment options.

  • Lucintel forecasts that, within the type category, therapeutic nuclear medicine is expected to witness higher growth over the forecast period.
  • Within the application category, oncology is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid evolution driven by technological advancements, increasing demand for personalized healthcare, and a growing focus on early diagnosis and treatment of various diseases. As healthcare providers seek more effective and less invasive options, the market is witnessing significant innovations in imaging techniques, radiopharmaceuticals, and treatment protocols. These developments are not only enhancing diagnostic accuracy but also expanding the scope of nuclear medicine applications across different medical fields. The following key trends highlight the transformative changes shaping this dynamic industry and their implications for stakeholders.

  • Technological Advancements in Imaging: The integration of hybrid imaging systems like PET/CT and PET/MRI is revolutionizing diagnostic capabilities. These advanced tools provide higher resolution images, better localization of disease, and improved patient outcomes. As technology becomes more sophisticated and accessible, healthcare providers can diagnose conditions earlier and with greater precision, leading to more targeted treatments and reduced healthcare costs.
  • Growing Use of Personalized Radiopharmaceuticals: The development of tailored radiopharmaceuticals is enabling personalized treatment plans for patients. These specialized compounds target specific disease markers, improving efficacy and minimizing side effects. This trend is particularly impactful in cancer therapy, where precision medicine is transforming patient management and increasing survival rates, thereby expanding the market for customized nuclear medicine solutions.
  • Rising Demand for Theragnostic: Theragnostic combines diagnostic imaging and targeted therapy using the same radiopharmaceuticals. This approach allows for real-time monitoring of treatment response and adjustment of therapy as needed. The increasing adoption of theragnostic is driving market growth by offering more effective, patient-specific treatment options, especially in oncology, and fostering innovation in radiopharmaceutical development.
  • Regulatory and Reimbursement Changes: Evolving regulatory frameworks and reimbursement policies are influencing market dynamics. Streamlined approval processes and expanded coverage for nuclear medicine procedures are encouraging adoption among healthcare providers. These changes facilitate faster market entry for new products and support broader clinical use, ultimately improving patient access to advanced diagnostic and therapeutic options.
  • Expansion into Emerging Markets: Growing healthcare infrastructure and rising awareness of nuclear medicine benefits are fueling market expansion in emerging economies. Investments in training, infrastructure, and regulatory frameworks are enabling these regions to adopt nuclear medicine technologies. This trend broadens the global market reach, diversifies revenue streams, and promotes innovation tailored to diverse healthcare needs.

In summary, these trends are collectively reshaping the nuclear medicine market by enhancing technological capabilities, enabling personalized treatments, expanding clinical applications, and broadening geographic reach. As a result, the industry is poised for sustained growth, improved patient outcomes, and increased integration of nuclear medicine into mainstream healthcare practices.

Recent Developments in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid advancements driven by technological innovations, increasing clinical applications, and growing demand for personalized healthcare. These developments are transforming diagnostic and therapeutic procedures, expanding market reach, and improving patient outcomes. Stakeholders are investing heavily in research and infrastructure to capitalize on emerging opportunities. As the industry evolves, understanding these key growth areas is essential for strategic planning and investment decisions in this dynamic sector.

  • Technology Advancements: Enhanced imaging techniques and radiopharmaceuticals are improving diagnostic accuracy and treatment efficacy. Innovations like hybrid imaging systems (PET/CT, SPECT/CT) enable precise localization of disease, reducing invasive procedures. These advancements are expanding clinical applications, attracting investments, and increasing adoption rates worldwide. The improved safety profiles and shorter procedure times are also boosting patient acceptance, ultimately driving market growth and fostering innovation in product development.
  • Increasing Clinical Applications: The scope of nuclear medicine is broadening with new indications such as targeted cancer therapy, cardiology, neurology, and infectious disease management. This diversification is driven by research demonstrating improved outcomes and reduced side effects compared to traditional treatments. As clinical evidence accumulates, healthcare providers are more inclined to adopt nuclear medicine procedures, leading to higher demand for radiopharmaceuticals and equipment. This trend is significantly expanding the market and encouraging new product development.
  • Rising Investment and Infrastructure: Governments and private entities are investing heavily in nuclear medicine infrastructure, including manufacturing facilities, research centers, and clinical settings. This investment aims to enhance regional capabilities, especially in emerging markets, and ensure supply chain stability. The expansion of infrastructure supports increased procedure volumes and facilitates the training of healthcare professionals. These developments are crucial for market growth, enabling wider access to nuclear medicine services and fostering innovation in the sector.
  • Regulatory Support and Reimbursement Policies: Favorable regulatory frameworks and reimbursement policies are encouraging the adoption of nuclear medicine procedures. Governments are streamlining approval processes for new radiopharmaceuticals and providing coverage for diagnostic and therapeutic applications. This support reduces financial barriers for healthcare providers and patients, accelerating market penetration. Clearer guidelines and reimbursement schemes are also fostering innovation and ensuring sustainable growth in the industry.
  • Market Expansion in Emerging Economies: Rapid economic growth and increasing healthcare awareness are driving nuclear medicine adoption in emerging markets. Investments in healthcare infrastructure, rising prevalence of chronic diseases, and government initiatives are expanding access to nuclear medicine services. Local manufacturing and partnerships are reducing costs and improving supply chains. This expansion is opening new revenue streams, diversifying the market, and positioning emerging economies as significant growth hubs for nuclear medicine.

These developments are collectively transforming the nuclear medicine market by enhancing technological capabilities, broadening clinical applications, and expanding infrastructure and access. Increased investments, supportive policies, and market expansion in emerging economies are driving growth and innovation. As a result, the industry is poised for sustained expansion, offering improved diagnostic and therapeutic options and ultimately benefiting patients worldwide. These trends are shaping a more dynamic, accessible, and innovative nuclear medicine landscape.

Strategic Growth Opportunities in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid growth driven by technological advancements, increasing disease prevalence, and expanding applications in diagnostics and therapy. Rising awareness and regulatory support further bolster market expansion. Strategic investments in research and development are unlocking new treatment options, while collaborations between healthcare providers and industry players enhance accessibility. As personalized medicine gains prominence, nuclear medicine is positioned to play a pivotal role in improving patient outcomes and healthcare efficiency globally.

  • Expanding Diagnostic Capabilities Through Advanced Imaging Techniques: Innovations in imaging technology, such as PET and SPECT, are enhancing diagnostic accuracy for cancer, cardiovascular, and neurological diseases. These advancements enable early detection, precise localization, and better disease monitoring, leading to improved treatment planning. The integration of hybrid imaging systems and novel radiotracers is further broadening clinical applications, making nuclear medicine indispensable in modern diagnostics and increasing market demand.
  • Growing Adoption of Targeted Radionuclide Therapy for Cancer Treatment: Targeted radionuclide therapy offers a promising approach for treating various cancers by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. The development of new radiopharmaceuticals and increasing clinical trials are expanding therapeutic options. Rising cancer incidence rates and personalized treatment strategies are driving adoption, positioning radionuclide therapy as a key growth segment within nuclear medicine, with significant market expansion potential.
  • Increasing Investment in Research and Development for New Radiopharmaceuticals: Continuous R&D efforts are leading to the discovery of novel radiotracers and therapeutic agents, broadening the scope of nuclear medicine. Investment from pharmaceutical companies and government agencies accelerates innovation, enabling the development of more effective, safer, and targeted diagnostic and therapeutic options. This focus on R&D is crucial for addressing unmet medical needs and sustaining long-term market growth.
  • Rising Awareness and Regulatory Support for Nuclear Medicine Procedures: Enhanced awareness among healthcare professionals and patients about the benefits of nuclear medicine is boosting procedure adoption. Regulatory agencies are streamlining approval processes and establishing guidelines that facilitate market entry for new radiopharmaceuticals. Supportive policies and reimbursement frameworks are further encouraging clinical use, thereby expanding the market and fostering innovation in nuclear medicine applications.
  • Increasing Use of Nuclear Medicine in Personalized Medicine and Precision Healthcare: The ability of nuclear medicine to provide molecular and functional insights supports personalized treatment approaches. Tailoring therapies based on individual patient profiles improves efficacy and reduces side effects. The integration of nuclear medicine with genomics and other diagnostic modalities is advancing precision healthcare, creating new opportunities for market growth and positioning nuclear medicine as a cornerstone of individualized patient management.

The overall impact of these growth opportunities is set to significantly expand the nuclear medicine market, enhancing diagnostic and therapeutic capabilities, improving patient outcomes, and fostering innovation. As technological, clinical, and regulatory landscapes evolve, the market is poised for sustained growth, attracting investments and collaborations that will shape the future of healthcare.

Nuclear Medicine Market Driver and Challenges

The nuclear medicine market is influenced by a variety of technological, economic, and regulatory factors that shape its growth and development. Advances in imaging technology and radiopharmaceuticals are driving innovation, while economic considerations such as healthcare spending and reimbursement policies impact market expansion. Regulatory frameworks ensure safety and efficacy but can also pose barriers to entry and innovation. Additionally, the increasing prevalence of chronic diseases and cancer globally fuels demand for diagnostic and therapeutic solutions. Navigating these complex drivers and challenges is essential for stakeholders aiming to capitalize on emerging opportunities and address potential obstacles within this dynamic industry.

The factors responsible for driving the nuclear medicine market include:-

  • Technological Advancements: The continuous development of high-resolution imaging devices and novel radiopharmaceuticals enhances diagnostic accuracy and therapeutic efficacy. Innovations like PET/CT and SPECT/CT improve disease detection, leading to increased adoption. These technological improvements reduce procedure times and improve patient outcomes, encouraging healthcare providers to invest in advanced nuclear medicine solutions. As research progresses, the pipeline of new radiotracers expands, further fueling market growth and opening new clinical applications.
  • Rising Prevalence of Chronic Diseases and Cancer: The global increase in cancer cases and chronic illnesses such as cardiovascular and neurological disorders significantly boosts demand for nuclear medicine procedures. These conditions require precise diagnosis and targeted treatment, which nuclear medicine provides effectively. As the burden of these diseases grows, healthcare systems are increasingly adopting nuclear medicine for early detection and management, thereby expanding the market. This trend is particularly prominent in emerging economies where healthcare infrastructure is improving.
  • Regulatory Approvals and Support: Stringent regulatory frameworks ensure the safety and efficacy of nuclear medicine products, fostering trust among healthcare providers and patients. Regulatory agencies like the FDA and EMA facilitate the approval process for new radiopharmaceuticals, encouraging innovation. Supportive policies and funding for research and development also accelerate product commercialization. These regulatory measures help maintain high standards, reduce risks, and promote market stability, ultimately encouraging investment and adoption across healthcare settings.
  • Growing Healthcare Infrastructure and Investment: Increasing healthcare expenditure and infrastructure development, especially in emerging markets, are vital drivers. Investments in modern imaging facilities and nuclear medicine departments enable wider access to advanced diagnostic and therapeutic options. Public and private sector funding supports the procurement of sophisticated equipment and training of personnel, expanding the reach of nuclear medicine services. This infrastructure growth not only improves patient access but also stimulates market growth by creating new opportunities for manufacturers and service providers.* Expanding Awareness and Acceptance: Growing awareness among healthcare professionals and patients about the benefits of nuclear medicine procedures is boosting adoption rates. Educational initiatives and clinical guidelines promote understanding of its advantages in early diagnosis and targeted therapy. Acceptance by clinicians as a standard diagnostic tool encourages routine use, while patient awareness about minimally invasive procedures enhances demand. This increased acceptance supports market expansion and encourages further innovation in the field.

The challenges facing the nuclear medicine market include:-

  • Regulatory and Safety Concerns: The complex regulatory landscape for nuclear medicine products can delay approvals and increase costs for manufacturers. Ensuring safety in handling radioactive materials requires strict compliance with safety standards, which can be resource-intensive. Concerns about radiation exposure and potential misuse also pose barriers to widespread adoption. These regulatory hurdles can slow down innovation and limit market entry, especially in regions with less developed regulatory frameworks, impacting overall growth.
  • High Costs and Reimbursement Issues: The high cost of advanced imaging equipment and radiopharmaceuticals limits accessibility, particularly in low- and middle-income countries. Reimbursement policies vary significantly across regions, affecting the financial viability of providers. Lack of adequate reimbursement discourages healthcare facilities from investing in nuclear medicine, thereby restricting patient access. Cost-related barriers hinder market expansion and slow the adoption of new technologies, emphasizing the need for policy reforms to improve affordability.
  • Short Half-life of Radiopharmaceuticals: Many radiotracers used in nuclear medicine have short half-lives, which complicates manufacturing, storage, and transportation. This logistical challenge limits the geographic reach of certain products and increases costs due to the need for nearby production facilities. It also restricts the availability of some innovative radiopharmaceuticals in remote or underserved areas, impacting patient access and market growth. Overcoming these limitations requires advancements in radiotracer stability and distribution infrastructure.

In summary, the nuclear medicine market is driven by technological innovations, increasing disease prevalence, supportive regulations, infrastructure development, and rising awareness. However, challenges such as regulatory complexities, high costs, reimbursement issues, and logistical constraints pose significant hurdles. These factors collectively influence the pace and scope of market growth, requiring strategic efforts from industry stakeholders to maximize opportunities while addressing obstacles. The overall impact is a dynamic landscape with substantial potential for expansion, provided that these challenges are effectively managed.

List of Nuclear Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies nuclear medicine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the nuclear medicine companies profiled in this report include-

  • Cardinal Health
  • GE Healthcare
  • Jubilant Pharma
  • Novartis
  • Curium Pharma
  • SIEMENS
  • Lantheus
  • Bracco Imaging
  • Bayer
  • Eli Lilly

Nuclear Medicine Market by Segment

The study includes a forecast for the global nuclear medicine market by type, application, and region.

Nuclear Medicine Market by Type [Value from 2019 to 2035]:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine

Nuclear Medicine Market by Application [Value from 2019 to 2035]:

  • Oncology
  • Thyroid
  • Cardiology
  • Others

Nuclear Medicine Market by Region [Value from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Nuclear Medicine Market

The nuclear medicine market has experienced significant growth driven by technological advancements, increasing prevalence of chronic diseases, and expanding applications in diagnostics and therapy. Countries are investing in research, infrastructure, and regulatory frameworks to enhance their capabilities. The United States leads in innovation and market size, while China and India are rapidly expanding due to rising healthcare demands. Germany and Japan are focusing on integrating advanced imaging techniques and personalized medicine approaches. These developments reflect a global shift towards more precise, effective, and minimally invasive diagnostic and treatment options, shaping the future landscape of nuclear medicine.

  • United States: The US market is characterized by technological innovation, with significant investments in PET and SPECT imaging systems. Growing adoption of theragnostic and personalized medicine is boosting demand. Regulatory approvals for new radiopharmaceuticals are accelerating, and key players are expanding manufacturing capacities. The US also emphasizes research collaborations and clinical trials to advance nuclear medicine applications.
  • China: China is experiencing rapid growth driven by increasing healthcare infrastructure and government initiatives to develop nuclear medicine. The country is investing heavily in new radiopharmaceutical production facilities and training programs. The adoption of advanced imaging modalities like PET/CT is rising, and domestic companies are gaining prominence through innovation and strategic partnerships.
  • Germany: Germany focuses on integrating advanced imaging technologies such as hybrid PET/MRI systems and developing novel radiopharmaceuticals. The country emphasizes research and development, supported by strong regulatory frameworks. Germany also leads in clinical trials and academic research, contributing to global advancements in nuclear medicine.
  • India: India is witnessing expanding nuclear medicine services due to rising chronic disease prevalence and healthcare access improvements. The market is driven by increasing adoption of PET/CT scans and the development of affordable radiopharmaceuticals. Government initiatives and private sector investments are enhancing infrastructure and training, fostering growth in both diagnostics and therapeutic applications.
  • Japan: Japan emphasizes innovation in nuclear medicine, particularly in personalized and targeted therapies. The country is investing in advanced imaging technologies and radiopharmaceutical research. Japan's focus on aging populations and cancer treatment is propelling market growth, with collaborations between academia and industry facilitating new product development and clinical applications.

Features of the Global Nuclear Medicine Market

  • Market Size Estimates: Nuclear medicine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
  • Segmentation Analysis: Nuclear medicine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Nuclear medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the nuclear medicine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the nuclear medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the nuclear medicine market by type (diagnostic nuclear medicine and therapeutic nuclear medicine), application (oncology, thyroid, cardiology, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Nuclear Medicine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Diagnostic Nuclear Medicine : Trends and Forecast (2019-2035)
  • 4.4 Therapeutic Nuclear Medicine : Trends and Forecast (2019-2035)

5. Global Nuclear Medicine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Oncology : Trends and Forecast (2019-2035)
  • 5.4 Thyroid : Trends and Forecast (2019-2035)
  • 5.5 Cardiology : Trends and Forecast (2019-2035)
  • 5.6 Others : Trends and Forecast (2019-2035)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Nuclear Medicine Market by Region

7. North American Nuclear Medicine Market

  • 7.1 Overview
  • 7.2 North American Nuclear Medicine Market by Type
  • 7.3 North American Nuclear Medicine Market by Application
  • 7.4 The United States Nuclear Medicine Market
  • 7.5 Canadian Nuclear Medicine Market
  • 7.6 Mexican Nuclear Medicine Market

8. European Nuclear Medicine Market

  • 8.1 Overview
  • 8.2 European Nuclear Medicine Market by Type
  • 8.3 European Nuclear Medicine Market by Application
  • 8.4 German Nuclear Medicine Market
  • 8.5 French Nuclear Medicine Market
  • 8.6 Italian Nuclear Medicine Market
  • 8.7 Spanish Nuclear Medicine Market
  • 8.8 The United Kingdom Nuclear Medicine Market

9. APAC Nuclear Medicine Market

  • 9.1 Overview
  • 9.2 APAC Nuclear Medicine Market by Type
  • 9.3 APAC Nuclear Medicine Market by Application
  • 9.4 Chinese Nuclear Medicine Market
  • 9.5 Indian Nuclear Medicine Market
  • 9.6 Japanese Nuclear Medicine Market
  • 9.7 South Korean Nuclear Medicine Market
  • 9.8 Indonesian Nuclear Medicine Market

10. ROW Nuclear Medicine Market

  • 10.1 Overview
  • 10.2 ROW Nuclear Medicine Market by Type
  • 10.3 ROW Nuclear Medicine Market by Application
  • 10.4 Middle Eastern Nuclear Medicine Market
  • 10.5 South American Nuclear Medicine Market
  • 10.6 African Nuclear Medicine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Nuclear Medicine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Cardinal Health
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 GE Healthcare
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Jubilant Pharma
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Novartis
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Curium Pharma
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 SIEMENS
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Lantheus
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Bracco Imaging
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Bayer
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Eli Lilly
    • Company Overview
    • Nuclear Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Nuclear Medicine Market
  • Figure 2.1: Usage of Nuclear Medicine Market
  • Figure 2.2: Classification of the Global Nuclear Medicine Market
  • Figure 2.3: Supply Chain of the Global Nuclear Medicine Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Nuclear Medicine Market
  • Figure 4.1: Global Nuclear Medicine Market by Type in 2019, 2025, and 2035
  • Figure 4.2: Trends of the Global Nuclear Medicine Market ($B) by Type
  • Figure 4.3: Forecast for the Global Nuclear Medicine Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Diagnostic Nuclear Medicine in the Global Nuclear Medicine Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Therapeutic Nuclear Medicine in the Global Nuclear Medicine Market (2019-2035)
  • Figure 5.1: Global Nuclear Medicine Market by Application in 2019, 2025, and 2035
  • Figure 5.2: Trends of the Global Nuclear Medicine Market ($B) by Application
  • Figure 5.3: Forecast for the Global Nuclear Medicine Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Oncology in the Global Nuclear Medicine Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Thyroid in the Global Nuclear Medicine Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Cardiology in the Global Nuclear Medicine Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Others in the Global Nuclear Medicine Market (2019-2035)
  • Figure 6.1: Trends of the Global Nuclear Medicine Market ($B) by Region (2019-2025)
  • Figure 6.2: Forecast for the Global Nuclear Medicine Market ($B) by Region (2026-2035)
  • Figure 7.1: Trends and Forecast for the North American Nuclear Medicine Market (2019-2035)
  • Figure 7.2: North American Nuclear Medicine Market by Type in 2019, 2025, and 2035
  • Figure 7.3: Trends of the North American Nuclear Medicine Market ($B) by Type (2019-2025)
  • Figure 7.4: Forecast for the North American Nuclear Medicine Market ($B) by Type (2026-2035)
  • Figure 7.5: North American Nuclear Medicine Market by Application in 2019, 2025, and 2035
  • Figure 7.6: Trends of the North American Nuclear Medicine Market ($B) by Application (2019-2025)
  • Figure 7.7: Forecast for the North American Nuclear Medicine Market ($B) by Application (2026-2035)
  • Figure 7.8: Trends and Forecast for the United States Nuclear Medicine Market ($B) (2019-2035)
  • Figure 7.9: Trends and Forecast for the Mexican Nuclear Medicine Market ($B) (2019-2035)
  • Figure 7.10: Trends and Forecast for the Canadian Nuclear Medicine Market ($B) (2019-2035)
  • Figure 8.1: Trends and Forecast for the European Nuclear Medicine Market (2019-2035)
  • Figure 8.2: European Nuclear Medicine Market by Type in 2019, 2025, and 2035
  • Figure 8.3: Trends of the European Nuclear Medicine Market ($B) by Type (2019-2025)
  • Figure 8.4: Forecast for the European Nuclear Medicine Market ($B) by Type (2026-2035)
  • Figure 8.5: European Nuclear Medicine Market by Application in 2019, 2025, and 2035
  • Figure 8.6: Trends of the European Nuclear Medicine Market ($B) by Application (2019-2025)
  • Figure 8.7: Forecast for the European Nuclear Medicine Market ($B) by Application (2026-2035)
  • Figure 8.8: Trends and Forecast for the German Nuclear Medicine Market ($B) (2019-2035)
  • Figure 8.9: Trends and Forecast for the French Nuclear Medicine Market ($B) (2019-2035)
  • Figure 8.10: Trends and Forecast for the Spanish Nuclear Medicine Market ($B) (2019-2035)
  • Figure 8.11: Trends and Forecast for the Italian Nuclear Medicine Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the United Kingdom Nuclear Medicine Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the APAC Nuclear Medicine Market (2019-2035)
  • Figure 9.2: APAC Nuclear Medicine Market by Type in 2019, 2025, and 2035
  • Figure 9.3: Trends of the APAC Nuclear Medicine Market ($B) by Type (2019-2025)
  • Figure 9.4: Forecast for the APAC Nuclear Medicine Market ($B) by Type (2026-2035)
  • Figure 9.5: APAC Nuclear Medicine Market by Application in 2019, 2025, and 2035
  • Figure 9.6: Trends of the APAC Nuclear Medicine Market ($B) by Application (2019-2025)
  • Figure 9.7: Forecast for the APAC Nuclear Medicine Market ($B) by Application (2026-2035)
  • Figure 9.8: Trends and Forecast for the Japanese Nuclear Medicine Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Indian Nuclear Medicine Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Chinese Nuclear Medicine Market ($B) (2019-2035)
  • Figure 9.11: Trends and Forecast for the South Korean Nuclear Medicine Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the Indonesian Nuclear Medicine Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the ROW Nuclear Medicine Market (2019-2035)
  • Figure 10.2: ROW Nuclear Medicine Market by Type in 2019, 2025, and 2035
  • Figure 10.3: Trends of the ROW Nuclear Medicine Market ($B) by Type (2019-2025)
  • Figure 10.4: Forecast for the ROW Nuclear Medicine Market ($B) by Type (2026-2035)
  • Figure 10.5: ROW Nuclear Medicine Market by Application in 2019, 2025, and 2035
  • Figure 10.6: Trends of the ROW Nuclear Medicine Market ($B) by Application (2019-2025)
  • Figure 10.7: Forecast for the ROW Nuclear Medicine Market ($B) by Application (2026-2035)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Nuclear Medicine Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the South American Nuclear Medicine Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the African Nuclear Medicine Market ($B) (2019-2035)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Nuclear Medicine Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Nuclear Medicine Market (2025)
  • Figure 12.1: Growth Opportunities for the Global Nuclear Medicine Market by Type
  • Figure 12.2: Growth Opportunities for the Global Nuclear Medicine Market by Application
  • Figure 12.3: Growth Opportunities for the Global Nuclear Medicine Market by Region
  • Figure 12.4: Emerging Trends in the Global Nuclear Medicine Market

List of Tables

  • Table 1.1: Growth Rate (%, 2024-2025) and CAGR (%, 2026-2035) of the Nuclear Medicine Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Nuclear Medicine Market by Region
  • Table 1.3: Global Nuclear Medicine Market Parameters and Attributes
  • Table 3.1: Trends of the Global Nuclear Medicine Market (2019-2025)
  • Table 3.2: Forecast for the Global Nuclear Medicine Market (2026-2035)
  • Table 4.1: Attractiveness Analysis for the Global Nuclear Medicine Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Nuclear Medicine Market (2019-2025)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Nuclear Medicine Market (2026-2035)
  • Table 4.4: Trends of Diagnostic Nuclear Medicine in the Global Nuclear Medicine Market (2019-2025)
  • Table 4.5: Forecast for Diagnostic Nuclear Medicine in the Global Nuclear Medicine Market (2026-2035)
  • Table 4.6: Trends of Therapeutic Nuclear Medicine in the Global Nuclear Medicine Market (2019-2025)
  • Table 4.7: Forecast for Therapeutic Nuclear Medicine in the Global Nuclear Medicine Market (2026-2035)
  • Table 5.1: Attractiveness Analysis for the Global Nuclear Medicine Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Nuclear Medicine Market (2019-2025)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Nuclear Medicine Market (2026-2035)
  • Table 5.4: Trends of Oncology in the Global Nuclear Medicine Market (2019-2025)
  • Table 5.5: Forecast for Oncology in the Global Nuclear Medicine Market (2026-2035)
  • Table 5.6: Trends of Thyroid in the Global Nuclear Medicine Market (2019-2025)
  • Table 5.7: Forecast for Thyroid in the Global Nuclear Medicine Market (2026-2035)
  • Table 5.8: Trends of Cardiology in the Global Nuclear Medicine Market (2019-2025)
  • Table 5.9: Forecast for Cardiology in the Global Nuclear Medicine Market (2026-2035)
  • Table 5.10: Trends of Others in the Global Nuclear Medicine Market (2019-2025)
  • Table 5.11: Forecast for Others in the Global Nuclear Medicine Market (2026-2035)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Nuclear Medicine Market (2019-2025)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Nuclear Medicine Market (2026-2035)
  • Table 7.1: Trends of the North American Nuclear Medicine Market (2019-2025)
  • Table 7.2: Forecast for the North American Nuclear Medicine Market (2026-2035)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Nuclear Medicine Market (2019-2025)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Nuclear Medicine Market (2026-2035)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Nuclear Medicine Market (2019-2025)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Nuclear Medicine Market (2026-2035)
  • Table 7.7: Trends and Forecast for the United States Nuclear Medicine Market (2019-2035)
  • Table 7.8: Trends and Forecast for the Mexican Nuclear Medicine Market (2019-2035)
  • Table 7.9: Trends and Forecast for the Canadian Nuclear Medicine Market (2019-2035)
  • Table 8.1: Trends of the European Nuclear Medicine Market (2019-2025)
  • Table 8.2: Forecast for the European Nuclear Medicine Market (2026-2035)
  • Table 8.3: Market Size and CAGR of Various Type in the European Nuclear Medicine Market (2019-2025)
  • Table 8.4: Market Size and CAGR of Various Type in the European Nuclear Medicine Market (2026-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the European Nuclear Medicine Market (2019-2025)
  • Table 8.6: Market Size and CAGR of Various Application in the European Nuclear Medicine Market (2026-2035)
  • Table 8.7: Trends and Forecast for the German Nuclear Medicine Market (2019-2035)
  • Table 8.8: Trends and Forecast for the French Nuclear Medicine Market (2019-2035)
  • Table 8.9: Trends and Forecast for the Spanish Nuclear Medicine Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Italian Nuclear Medicine Market (2019-2035)
  • Table 8.11: Trends and Forecast for the United Kingdom Nuclear Medicine Market (2019-2035)
  • Table 9.1: Trends of the APAC Nuclear Medicine Market (2019-2025)
  • Table 9.2: Forecast for the APAC Nuclear Medicine Market (2026-2035)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Nuclear Medicine Market (2019-2025)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Nuclear Medicine Market (2026-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Nuclear Medicine Market (2019-2025)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Nuclear Medicine Market (2026-2035)
  • Table 9.7: Trends and Forecast for the Japanese Nuclear Medicine Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Indian Nuclear Medicine Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Chinese Nuclear Medicine Market (2019-2035)
  • Table 9.10: Trends and Forecast for the South Korean Nuclear Medicine Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Indonesian Nuclear Medicine Market (2019-2035)
  • Table 10.1: Trends of the ROW Nuclear Medicine Market (2019-2025)
  • Table 10.2: Forecast for the ROW Nuclear Medicine Market (2026-2035)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Nuclear Medicine Market (2019-2025)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Nuclear Medicine Market (2026-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Nuclear Medicine Market (2019-2025)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Nuclear Medicine Market (2026-2035)
  • Table 10.7: Trends and Forecast for the Middle Eastern Nuclear Medicine Market (2019-2035)
  • Table 10.8: Trends and Forecast for the South American Nuclear Medicine Market (2019-2035)
  • Table 10.9: Trends and Forecast for the African Nuclear Medicine Market (2019-2035)
  • Table 11.1: Product Mapping of Nuclear Medicine Suppliers Based on Segments
  • Table 11.2: Operational Integration of Nuclear Medicine Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Nuclear Medicine Revenue
  • Table 12.1: New Product Launches by Major Nuclear Medicine Producers (2019-2025)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Nuclear Medicine Market